Merck & Company Inc (MRK)vsProtalix Biotherapeutics Inc (PLX)
MRK
Merck & Company Inc
$146.87
-0.19%
HEALTHCARE · Cap: $355.10B
PLX
Protalix Biotherapeutics Inc
$2.69
-0.37%
HEALTHCARE · Cap: $219.96M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 82472% more annual revenue ($66.57B vs $80.62M). PLX leads profitability with a 23.5% profit margin vs 4.8%. PLX trades at a lower P/E of 11.4x. PLX earns a higher WallStSmart Score of 64/100 (C+).
MRK
Hold36
out of 100
Grade: F
PLX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$146.87
$63.83 premium
Intrinsic value data unavailable for PLX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Earnings expanding 2241.0% YoY
Every $100 of equity generates 23 in profit
Keeps 24 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 23.5%
Areas to Watch
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Weak financial health signals
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PLX
The strongest argument for PLX centers on P/E Ratio, EPS Growth, Return on Equity. Profitability is solid with margins at 23.5% and operating margin at 23.5%. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
MRK profiles as a value stock while PLX is a growth play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.23 — expect wider price swings.
PLX is growing revenue faster at 27.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
PLX scores higher overall (64/100 vs 36/100), backed by strong 23.5% margins and 27.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?